{"gene":"GCNT2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2004,"finding":"A homozygous nonsense mutation (W328X) in GCNT2 exon-2 causes loss of I-branching glucosaminyl transferase activity, resulting in autosomal recessive congenital cataracts and the adult i blood group phenotype, demonstrating GCNT2's dual role in lens and reticulocytes.","method":"Linkage mapping, PCR-based mutation analysis (direct sequencing), blood group typing","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — linkage mapping plus sequencing plus blood group phenotype confirmation, single lab, multiple orthogonal methods","pmids":["15161861"],"is_preprint":false},{"year":2011,"finding":"A homozygous ~93 kb genomic deletion at the GCNT2 locus, mediated by Alu-Alu repeat recombination and encompassing exons 1B, 1C, 2, and 3, abolishes GCNT2 function causing congenital cataracts and the adult i blood group phenotype.","method":"Homozygosity mapping, long-range PCR, breakpoint sequencing, blood group typing","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (homozygosity mapping, breakpoint sequencing, phenotypic confirmation), single lab","pmids":["21761136"],"is_preprint":false},{"year":2016,"finding":"The GCNT2B isoform (driven by exon 1B) is the isoform specifically required for lens function, while the GCNT2C isoform is the only one expressed in red blood cells; deletions affecting only exon 1B/A (sparing 1C) cause congenital cataracts without the i blood group phenotype.","method":"Whole-exome sequencing, chromosomal walking/deletion mapping, isoform-specific genotype-phenotype analysis","journal":"BMC medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — deletion breakpoint mapping combined with isoform-specific genotype-phenotype correlation, single lab, two orthogonal methods","pmids":["27609212"],"is_preprint":false},{"year":2014,"finding":"GCNT2 cooperates with β3GnT2 to synthesize N-linked poly-N-acetyllactosamine (PLN) glycans; co-transfection of both enzymes in HEK293T cells produces high levels of PLN on the cell surface and on adenylyl cyclase 3, whereas either enzyme alone is insufficient, indicating GCNT2 provides β1,6-branches that promote PLN chain extension.","method":"Co-transfection in HEK293T cells, flow cytometry, immunofluorescence, glycan analysis","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reconstitution by co-expression with cell-surface glycan readout, single lab, multiple methods","pmids":["24105809"],"is_preprint":false},{"year":2018,"finding":"Loss of GCNT2 and I-branched glycans increases melanoma xenograft growth and colony formation while enhancing cell survival; conversely, GCNT2 overexpression decreases growth and increases cell death. Mechanistically, I-branched glycans on IGF receptors and integrins reduce signaling responses of these glycoprotein families.","method":"Xenograft experiments, colony formation assay, GCNT2 overexpression/knockdown, glycan profiling, receptor signaling assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (xenograft, glycan profiling, signaling assays), independent experimental validations within a single rigorous study","pmids":["30135430"],"is_preprint":false},{"year":2017,"finding":"miR-199a/b-5p directly binds the 3′ UTR of GCNT2 mRNA (validated by reporter assays and RNA-induced silencing complex-trap assays) and represses GCNT2 expression, thereby suppressing I antigen production; during EMT in colon cancer cells, miR-199a/b-5p is downregulated, allowing GCNT2 upregulation.","method":"Luciferase reporter assay, RISC-trap assay, GCNT2 knockdown/overexpression, EMT induction with EGF/bFGF","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding validated by reporter and RISC-trap assays, single lab, two orthogonal methods","pmids":["28542779"],"is_preprint":false},{"year":2018,"finding":"GCNT2 overexpression in esophageal squamous cell carcinoma cells promotes EMT (increased N-cadherin and vimentin, decreased E-cadherin) and enhances migration and invasion, while GCNT2 knockdown has the opposite effect.","method":"GCNT2 overexpression and knockdown in ESCC cell lines, Western blot for EMT markers, migration/invasion assays","journal":"Cell biochemistry and function","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple cell lines and orthogonal assays, single lab, no in vivo rescue","pmids":["30575058"],"is_preprint":false},{"year":2025,"finding":"GCNT2 overexpression in bladder cancer cells enhances susceptibility to NK cell-mediated cytotoxicity and induces cytotoxic granule release from NK cells, while GCNT2 knockdown promotes immune evasion, indicating that I-antigen glycans synthesized by GCNT2 are required for NK cell recognition.","method":"GCNT2 overexpression/knockdown in bladder cancer cell lines, in vitro NK cell cytotoxicity assay, ELISA for cytotoxic granule release","journal":"Biomedicines","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional in vitro assay with NK cells, single lab, single study","pmids":["40149658"],"is_preprint":false},{"year":2025,"finding":"GCNT2 knockdown in MC3T3-E1 osteoblasts promotes osteoblast differentiation (increased ALP, alizarin red staining, Runx2, OCN, OPN); this pro-differentiation effect is abolished by the PI3K inhibitor LY294002, placing GCNT2 upstream of the PI3K/AKT/mTOR signaling pathway in osteoblasts.","method":"GCNT2 knockdown in osteoblast cell line, ALP/ARS staining, Western blot, PI3K inhibitor rescue experiment","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell-line model, pharmacological inhibitor only, no direct pathway confirmation","pmids":["41298859"],"is_preprint":false},{"year":2026,"finding":"A truncating variant limited to exon 1B of GCNT2 (NM_001491.3: c.760dup p.H254Pfs*2) found in trans with a deletion encompassing exons 1B and 1C causes congenital cataracts, establishing that the GCNT2B isoform (containing exon 1B) is a clinically relevant transcript for lens function.","method":"Next-generation sequencing, copy-number deletion mapping, genotype-phenotype correlation","journal":"American journal of medical genetics. Part A","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single case report, genotype-phenotype inference, no direct biochemical validation","pmids":["41813616"],"is_preprint":false}],"current_model":"GCNT2 encodes a β1,6-N-acetylglucosaminyltransferase that creates I-branched polylactosamine glycans on N-glycan core structures; it cooperates with β3GnT2 to extend poly-N-acetyllactosamine chains, modifies surface glycoproteins including IGF receptors and integrins to dampen their signaling, enables NK cell recognition of tumor cells, and its lens-specific isoform (GCNT2B, exon 1B) is required for lens transparency, while the erythrocyte-specific isoform (GCNT2C) governs blood group I antigen expression—with loss-of-function mutations or promoter methylation silencing causing congenital cataracts, adult i blood group phenotype, and context-dependent changes in cancer cell behavior including EMT, migration, and immune evasion."},"narrative":{"mechanistic_narrative":"GCNT2 encodes a β1,6-N-acetylglucosaminyltransferase that constructs I-branched poly-N-acetyllactosamine glycans, acting through tissue-specific isoforms to govern lens transparency, erythrocyte I/i blood group identity, and the glycosylation state of cell-surface receptors [PMID:15161861, PMID:30135430]. In glycan synthesis, GCNT2 cooperates with β3GnT2: the two enzymes together generate N-linked poly-N-acetyllactosamine on cell-surface glycoproteins, with GCNT2 supplying the β1,6-branch that licenses chain extension, an activity neither enzyme produces alone [PMID:24105809]. The locus is organized into alternative first exons that generate functionally segregated isoforms—the exon-1B-driven GCNT2B isoform is specifically required for lens function, while the GCNT2C isoform is the sole transcript expressed in red blood cells and dictates I-antigen display [PMID:27609212]. Loss-of-function lesions—nonsense mutation, large Alu-mediated genomic deletions, or isoform-restricted truncating variants—abolish I-branching activity and cause autosomal recessive congenital cataracts and the adult i blood group phenotype, with deletions sparing exon 1C producing cataracts without the blood group change [PMID:15161861, PMID:21761136, PMID:27609212]. In cancer, I-branched glycans installed by GCNT2 decorate IGF receptors and integrins to dampen their signaling and restrain melanoma growth, and GCNT2-dependent I-antigens are required for NK-cell recognition of tumor cells [PMID:30135430, PMID:40149658]; expression is restrained by miR-199a/b-5p, whose loss during EMT permits GCNT2 upregulation [PMID:28542779].","teleology":[{"year":2004,"claim":"Established that GCNT2 enzymatic activity is jointly required in lens and erythroid lineages, linking a single glycosyltransferase to two distinct phenotypes.","evidence":"Linkage mapping and direct sequencing identifying a homozygous W328X nonsense mutation with blood group typing in cataract patients","pmids":["15161861"],"confidence":"Medium","gaps":["Did not resolve which transcript/isoform mediates each phenotype","No biochemical reconstitution of lost enzymatic activity"]},{"year":2011,"claim":"Showed that structural genomic loss at the locus, not only point mutation, abolishes GCNT2 function, defining a recombination-driven mutational mechanism.","evidence":"Homozygosity mapping and breakpoint sequencing of a ~93 kb Alu-Alu-mediated deletion with phenotypic confirmation","pmids":["21761136"],"confidence":"Medium","gaps":["Did not dissect isoform-specific contributions since deletion removed multiple exons"]},{"year":2014,"claim":"Defined the biochemical logic of I-branch synthesis, showing GCNT2 must act in concert with β3GnT2 to extend poly-N-acetyllactosamine chains.","evidence":"Co-transfection of GCNT2 and β3GnT2 in HEK293T cells with cell-surface glycan readout on adenylyl cyclase 3","pmids":["24105809"],"confidence":"Medium","gaps":["Enzymatic kinetics and stoichiometry of cooperation not determined","Endogenous substrate range not mapped"]},{"year":2016,"claim":"Resolved the genotype-phenotype puzzle by assigning lens function to the exon-1B GCNT2B isoform and erythroid I-antigen to GCNT2C.","evidence":"Whole-exome sequencing and deletion mapping with isoform-specific genotype-phenotype correlation","pmids":["27609212"],"confidence":"Medium","gaps":["No direct demonstration of isoform expression in human lens tissue","Regulatory basis of tissue-specific exon usage unknown"]},{"year":2017,"claim":"Identified a post-transcriptional control circuit, showing miR-199a/b-5p directly represses GCNT2 and links its expression to EMT state.","evidence":"Luciferase reporter and RISC-trap assays plus EMT induction in colon cancer cells","pmids":["28542779"],"confidence":"Medium","gaps":["Functional consequence of GCNT2 derepression on tumor behavior not tested here","Other regulators of GCNT2 not addressed"]},{"year":2018,"claim":"Established GCNT2 as a tumor-suppressive glycosylation switch in melanoma, with I-branched glycans dampening IGF receptor and integrin signaling.","evidence":"Xenograft, colony formation, overexpression/knockdown, glycan profiling and receptor signaling assays","pmids":["30135430"],"confidence":"High","gaps":["Direct glycan site mapping on individual receptors not resolved","Mechanism of signaling attenuation by branching not fully defined"]},{"year":2018,"claim":"Revealed context-dependent, opposite tumor behavior, with GCNT2 promoting EMT, migration and invasion in esophageal carcinoma cells.","evidence":"Overexpression and knockdown in ESCC cell lines with EMT marker Western blots and migration/invasion assays","pmids":["30575058"],"confidence":"Medium","gaps":["No in vivo validation","Molecular basis of pro-EMT effect unidentified","Reconciliation with tumor-suppressive role in melanoma unresolved"]},{"year":2025,"claim":"Connected GCNT2 glycans to anti-tumor immunity, showing I-antigens are required for NK-cell recognition of bladder cancer cells.","evidence":"Overexpression/knockdown in bladder cancer lines with in vitro NK cytotoxicity assays and granule-release ELISA","pmids":["40149658"],"confidence":"Medium","gaps":["NK receptor that reads I-antigen not identified","No in vivo immune validation"]},{"year":2025,"claim":"Implicated GCNT2 in osteoblast differentiation upstream of PI3K/AKT/mTOR signaling.","evidence":"Knockdown in MC3T3-E1 osteoblasts with differentiation markers and LY294002 inhibitor rescue","pmids":["41298859"],"confidence":"Low","gaps":["Pharmacological inhibitor only, no direct pathway confirmation","Single cell-line model, no in vivo data","Glycan substrate linking GCNT2 to PI3K signaling not identified"]},{"year":2026,"claim":"Reinforced that the exon-1B GCNT2B transcript is clinically required for lens function via an isoform-restricted truncating variant.","evidence":"Next-generation sequencing and copy-number mapping with genotype-phenotype correlation in a cataract case","pmids":["41813616"],"confidence":"Low","gaps":["Single case report, no biochemical validation","Variant effect on enzyme activity not measured"]},{"year":null,"claim":"How GCNT2's I-branching produces opposite tumor outcomes across tissues, and which receptors and glycan sites mediate immune and signaling effects, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of isoform-specific substrate selection","Direct glycan acceptor sites on IGF receptors/integrins unmapped","NK receptor recognizing I-antigen unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,4]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,4]}],"complexes":[],"partners":["B3GNT2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8N0V5","full_name":"N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase","aliases":["I-branching enzyme","IGNT"],"length_aa":402,"mass_kda":45.9,"function":"Branching enzyme that converts linear into branched poly-N-acetyllactosaminoglycans. Introduces the blood group I antigen during embryonic development. It is closely associated with the development and maturation of erythroid cells Determines the expression of the blood group I antigen in erythrocytes","subcellular_location":"Golgi apparatus membrane","url":"https://www.uniprot.org/uniprotkb/Q8N0V5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GCNT2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GCNT2","total_profiled":1310},"omim":[{"mim_id":"616782","title":"GLUCOSAMINYL (N-ACETYL) TRANSFERASE 4; GCNT4","url":"https://www.omim.org/entry/616782"},{"mim_id":"606836","title":"GLUCOSAMINYL (N-ACETYL) TRANSFERASE 3, MUCIN-TYPE; GCNT3","url":"https://www.omim.org/entry/606836"},{"mim_id":"600429","title":"GLUCOSAMINYL (N-ACETYL) TRANSFERASE 2, I-BRANCHING ENZYME; GCNT2","url":"https://www.omim.org/entry/600429"},{"mim_id":"153380","title":"LYMPHOCYTE CYTOSOL POLYPEPTIDE, 20-KD","url":"https://www.omim.org/entry/153380"},{"mim_id":"116700","title":"CATARACT 13 WITH ADULT i PHENOTYPE; CTRCT13","url":"https://www.omim.org/entry/116700"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"prostate","ntpm":13.7}],"url":"https://www.proteinatlas.org/search/GCNT2"},"hgnc":{"alias_symbol":["IGNT","NAGCT1","bA421M1.1","bA360O19.2","ULG3"],"prev_symbol":["NACGT1","II","GCNT5","CCAT"]},"alphafold":{"accession":"Q8N0V5","domains":[{"cath_id":"3.90.550","chopping":"75-324","consensus_level":"medium","plddt":97.0123,"start":75,"end":324}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N0V5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N0V5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N0V5-F1-predicted_aligned_error_v6.png","plddt_mean":91.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GCNT2","jax_strain_url":"https://www.jax.org/strain/search?query=GCNT2"},"sequence":{"accession":"Q8N0V5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N0V5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N0V5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N0V5"}},"corpus_meta":[{"pmid":"15161861","id":"PMC_15161861","title":"A nonsense mutation in the glucosaminyl (N-acetyl) transferase 2 gene (GCNT2): association with autosomal recessive congenital cataracts.","date":"2004","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/15161861","citation_count":76,"is_preprint":false},{"pmid":"30135430","id":"PMC_30135430","title":"Loss of GCNT2/I-branched glycans enhances melanoma growth and survival.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30135430","citation_count":53,"is_preprint":false},{"pmid":"28542779","id":"PMC_28542779","title":"Downregulation of miR-199a/b-5p is associated with GCNT2 induction upon epithelial-mesenchymal transition in colon cancer.","date":"2017","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/28542779","citation_count":35,"is_preprint":false},{"pmid":"25750292","id":"PMC_25750292","title":"Aberrant methylation of GCNT2 is tightly related to lymph node metastasis of primary CRC.","date":"2015","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25750292","citation_count":26,"is_preprint":false},{"pmid":"21761136","id":"PMC_21761136","title":"An Alu repeat-mediated genomic GCNT2 deletion underlies congenital cataracts and adult i blood group.","date":"2011","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21761136","citation_count":16,"is_preprint":false},{"pmid":"30575058","id":"PMC_30575058","title":"GCNT2 induces epithelial-mesenchymal transition and promotes migration and invasion in esophageal squamous cell carcinoma cells.","date":"2018","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/30575058","citation_count":15,"is_preprint":false},{"pmid":"24105809","id":"PMC_24105809","title":"N-linked polylactosamine glycan synthesis is regulated by co-expression of β3GnT2 and GCNT2.","date":"2014","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24105809","citation_count":10,"is_preprint":false},{"pmid":"38770735","id":"PMC_38770735","title":"Inhibition of miR-199b-5p reduces pathological alterations in osteoarthritis by potentially targeting Fzd6 and Gcnt2.","date":"2024","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/38770735","citation_count":10,"is_preprint":false},{"pmid":"27936067","id":"PMC_27936067","title":"Deletion at the GCNT2 Locus Causes Autosomal Recessive Congenital Cataracts.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27936067","citation_count":10,"is_preprint":false},{"pmid":"27609212","id":"PMC_27609212","title":"Case report of homozygous deletion involving the first coding exons of GCNT2 isoforms A and B and part of the upstream region of TFAP2A in congenital cataract.","date":"2016","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27609212","citation_count":8,"is_preprint":false},{"pmid":"40149658","id":"PMC_40149658","title":"Low GCNT2/I-Branching Glycan Expression Is Associated with Bladder Cancer Aggressiveness.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/40149658","citation_count":2,"is_preprint":false},{"pmid":"28224043","id":"PMC_28224043","title":"Pleiotropic effect of a novel mutation in GCNT2 causing congenital cataract and a rare adult i blood group phenotype.","date":"2017","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/28224043","citation_count":2,"is_preprint":false},{"pmid":"41298859","id":"PMC_41298859","title":"Knockdown of GCNT2 promoted osteoblast differentiation by activating PI3K/AKT/mTOR pathway in osteoblasts.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41298859","citation_count":1,"is_preprint":false},{"pmid":"38849695","id":"PMC_38849695","title":"Long Non-Coding RNA PCAT19 Suppresses Cell Proliferation and Angiogenesis in Coronary Artery Disease through Interaction with GCNT2.","date":"2024","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/38849695","citation_count":1,"is_preprint":false},{"pmid":"40993090","id":"PMC_40993090","title":"Inhibition of miR-199b-5p Suppresses the Tuberculosis-Induced Inflammation in Spinal Tuberculosis via Targeting Gcnt2.","date":"2025","source":"The Tohoku journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40993090","citation_count":1,"is_preprint":false},{"pmid":"41713900","id":"PMC_41713900","title":"Bilateral juvenile-onset cataracts associated with GCNT2 variants.","date":"2026","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41713900","citation_count":0,"is_preprint":false},{"pmid":"41813616","id":"PMC_41813616","title":"Case Report With Biallelic Variants in GCNT2 Implicates Exon 1B in Congenital Cataracts.","date":"2026","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/41813616","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10593,"output_tokens":2456,"usd":0.034309,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9572,"output_tokens":3032,"usd":0.06183,"stage2_stop_reason":"end_turn"},"total_usd":0.096139,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"A homozygous nonsense mutation (W328X) in GCNT2 exon-2 causes loss of I-branching glucosaminyl transferase activity, resulting in autosomal recessive congenital cataracts and the adult i blood group phenotype, demonstrating GCNT2's dual role in lens and reticulocytes.\",\n      \"method\": \"Linkage mapping, PCR-based mutation analysis (direct sequencing), blood group typing\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — linkage mapping plus sequencing plus blood group phenotype confirmation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15161861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A homozygous ~93 kb genomic deletion at the GCNT2 locus, mediated by Alu-Alu repeat recombination and encompassing exons 1B, 1C, 2, and 3, abolishes GCNT2 function causing congenital cataracts and the adult i blood group phenotype.\",\n      \"method\": \"Homozygosity mapping, long-range PCR, breakpoint sequencing, blood group typing\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (homozygosity mapping, breakpoint sequencing, phenotypic confirmation), single lab\",\n      \"pmids\": [\"21761136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The GCNT2B isoform (driven by exon 1B) is the isoform specifically required for lens function, while the GCNT2C isoform is the only one expressed in red blood cells; deletions affecting only exon 1B/A (sparing 1C) cause congenital cataracts without the i blood group phenotype.\",\n      \"method\": \"Whole-exome sequencing, chromosomal walking/deletion mapping, isoform-specific genotype-phenotype analysis\",\n      \"journal\": \"BMC medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — deletion breakpoint mapping combined with isoform-specific genotype-phenotype correlation, single lab, two orthogonal methods\",\n      \"pmids\": [\"27609212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GCNT2 cooperates with β3GnT2 to synthesize N-linked poly-N-acetyllactosamine (PLN) glycans; co-transfection of both enzymes in HEK293T cells produces high levels of PLN on the cell surface and on adenylyl cyclase 3, whereas either enzyme alone is insufficient, indicating GCNT2 provides β1,6-branches that promote PLN chain extension.\",\n      \"method\": \"Co-transfection in HEK293T cells, flow cytometry, immunofluorescence, glycan analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reconstitution by co-expression with cell-surface glycan readout, single lab, multiple methods\",\n      \"pmids\": [\"24105809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss of GCNT2 and I-branched glycans increases melanoma xenograft growth and colony formation while enhancing cell survival; conversely, GCNT2 overexpression decreases growth and increases cell death. Mechanistically, I-branched glycans on IGF receptors and integrins reduce signaling responses of these glycoprotein families.\",\n      \"method\": \"Xenograft experiments, colony formation assay, GCNT2 overexpression/knockdown, glycan profiling, receptor signaling assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (xenograft, glycan profiling, signaling assays), independent experimental validations within a single rigorous study\",\n      \"pmids\": [\"30135430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-199a/b-5p directly binds the 3′ UTR of GCNT2 mRNA (validated by reporter assays and RNA-induced silencing complex-trap assays) and represses GCNT2 expression, thereby suppressing I antigen production; during EMT in colon cancer cells, miR-199a/b-5p is downregulated, allowing GCNT2 upregulation.\",\n      \"method\": \"Luciferase reporter assay, RISC-trap assay, GCNT2 knockdown/overexpression, EMT induction with EGF/bFGF\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding validated by reporter and RISC-trap assays, single lab, two orthogonal methods\",\n      \"pmids\": [\"28542779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GCNT2 overexpression in esophageal squamous cell carcinoma cells promotes EMT (increased N-cadherin and vimentin, decreased E-cadherin) and enhances migration and invasion, while GCNT2 knockdown has the opposite effect.\",\n      \"method\": \"GCNT2 overexpression and knockdown in ESCC cell lines, Western blot for EMT markers, migration/invasion assays\",\n      \"journal\": \"Cell biochemistry and function\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple cell lines and orthogonal assays, single lab, no in vivo rescue\",\n      \"pmids\": [\"30575058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GCNT2 overexpression in bladder cancer cells enhances susceptibility to NK cell-mediated cytotoxicity and induces cytotoxic granule release from NK cells, while GCNT2 knockdown promotes immune evasion, indicating that I-antigen glycans synthesized by GCNT2 are required for NK cell recognition.\",\n      \"method\": \"GCNT2 overexpression/knockdown in bladder cancer cell lines, in vitro NK cell cytotoxicity assay, ELISA for cytotoxic granule release\",\n      \"journal\": \"Biomedicines\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional in vitro assay with NK cells, single lab, single study\",\n      \"pmids\": [\"40149658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GCNT2 knockdown in MC3T3-E1 osteoblasts promotes osteoblast differentiation (increased ALP, alizarin red staining, Runx2, OCN, OPN); this pro-differentiation effect is abolished by the PI3K inhibitor LY294002, placing GCNT2 upstream of the PI3K/AKT/mTOR signaling pathway in osteoblasts.\",\n      \"method\": \"GCNT2 knockdown in osteoblast cell line, ALP/ARS staining, Western blot, PI3K inhibitor rescue experiment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell-line model, pharmacological inhibitor only, no direct pathway confirmation\",\n      \"pmids\": [\"41298859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"A truncating variant limited to exon 1B of GCNT2 (NM_001491.3: c.760dup p.H254Pfs*2) found in trans with a deletion encompassing exons 1B and 1C causes congenital cataracts, establishing that the GCNT2B isoform (containing exon 1B) is a clinically relevant transcript for lens function.\",\n      \"method\": \"Next-generation sequencing, copy-number deletion mapping, genotype-phenotype correlation\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single case report, genotype-phenotype inference, no direct biochemical validation\",\n      \"pmids\": [\"41813616\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GCNT2 encodes a β1,6-N-acetylglucosaminyltransferase that creates I-branched polylactosamine glycans on N-glycan core structures; it cooperates with β3GnT2 to extend poly-N-acetyllactosamine chains, modifies surface glycoproteins including IGF receptors and integrins to dampen their signaling, enables NK cell recognition of tumor cells, and its lens-specific isoform (GCNT2B, exon 1B) is required for lens transparency, while the erythrocyte-specific isoform (GCNT2C) governs blood group I antigen expression—with loss-of-function mutations or promoter methylation silencing causing congenital cataracts, adult i blood group phenotype, and context-dependent changes in cancer cell behavior including EMT, migration, and immune evasion.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GCNT2 encodes a β1,6-N-acetylglucosaminyltransferase that constructs I-branched poly-N-acetyllactosamine glycans, acting through tissue-specific isoforms to govern lens transparency, erythrocyte I/i blood group identity, and the glycosylation state of cell-surface receptors [#0, #4]. In glycan synthesis, GCNT2 cooperates with β3GnT2: the two enzymes together generate N-linked poly-N-acetyllactosamine on cell-surface glycoproteins, with GCNT2 supplying the β1,6-branch that licenses chain extension, an activity neither enzyme produces alone [#3]. The locus is organized into alternative first exons that generate functionally segregated isoforms—the exon-1B-driven GCNT2B isoform is specifically required for lens function, while the GCNT2C isoform is the sole transcript expressed in red blood cells and dictates I-antigen display [#2]. Loss-of-function lesions—nonsense mutation, large Alu-mediated genomic deletions, or isoform-restricted truncating variants—abolish I-branching activity and cause autosomal recessive congenital cataracts and the adult i blood group phenotype, with deletions sparing exon 1C producing cataracts without the blood group change [#0, #1, #2]. In cancer, I-branched glycans installed by GCNT2 decorate IGF receptors and integrins to dampen their signaling and restrain melanoma growth, and GCNT2-dependent I-antigens are required for NK-cell recognition of tumor cells [#4, #7]; expression is restrained by miR-199a/b-5p, whose loss during EMT permits GCNT2 upregulation [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established that GCNT2 enzymatic activity is jointly required in lens and erythroid lineages, linking a single glycosyltransferase to two distinct phenotypes.\",\n      \"evidence\": \"Linkage mapping and direct sequencing identifying a homozygous W328X nonsense mutation with blood group typing in cataract patients\",\n      \"pmids\": [\"15161861\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not resolve which transcript/isoform mediates each phenotype\", \"No biochemical reconstitution of lost enzymatic activity\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed that structural genomic loss at the locus, not only point mutation, abolishes GCNT2 function, defining a recombination-driven mutational mechanism.\",\n      \"evidence\": \"Homozygosity mapping and breakpoint sequencing of a ~93 kb Alu-Alu-mediated deletion with phenotypic confirmation\",\n      \"pmids\": [\"21761136\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not dissect isoform-specific contributions since deletion removed multiple exons\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the biochemical logic of I-branch synthesis, showing GCNT2 must act in concert with β3GnT2 to extend poly-N-acetyllactosamine chains.\",\n      \"evidence\": \"Co-transfection of GCNT2 and β3GnT2 in HEK293T cells with cell-surface glycan readout on adenylyl cyclase 3\",\n      \"pmids\": [\"24105809\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymatic kinetics and stoichiometry of cooperation not determined\", \"Endogenous substrate range not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved the genotype-phenotype puzzle by assigning lens function to the exon-1B GCNT2B isoform and erythroid I-antigen to GCNT2C.\",\n      \"evidence\": \"Whole-exome sequencing and deletion mapping with isoform-specific genotype-phenotype correlation\",\n      \"pmids\": [\"27609212\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct demonstration of isoform expression in human lens tissue\", \"Regulatory basis of tissue-specific exon usage unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified a post-transcriptional control circuit, showing miR-199a/b-5p directly represses GCNT2 and links its expression to EMT state.\",\n      \"evidence\": \"Luciferase reporter and RISC-trap assays plus EMT induction in colon cancer cells\",\n      \"pmids\": [\"28542779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of GCNT2 derepression on tumor behavior not tested here\", \"Other regulators of GCNT2 not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established GCNT2 as a tumor-suppressive glycosylation switch in melanoma, with I-branched glycans dampening IGF receptor and integrin signaling.\",\n      \"evidence\": \"Xenograft, colony formation, overexpression/knockdown, glycan profiling and receptor signaling assays\",\n      \"pmids\": [\"30135430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct glycan site mapping on individual receptors not resolved\", \"Mechanism of signaling attenuation by branching not fully defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed context-dependent, opposite tumor behavior, with GCNT2 promoting EMT, migration and invasion in esophageal carcinoma cells.\",\n      \"evidence\": \"Overexpression and knockdown in ESCC cell lines with EMT marker Western blots and migration/invasion assays\",\n      \"pmids\": [\"30575058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo validation\", \"Molecular basis of pro-EMT effect unidentified\", \"Reconciliation with tumor-suppressive role in melanoma unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected GCNT2 glycans to anti-tumor immunity, showing I-antigens are required for NK-cell recognition of bladder cancer cells.\",\n      \"evidence\": \"Overexpression/knockdown in bladder cancer lines with in vitro NK cytotoxicity assays and granule-release ELISA\",\n      \"pmids\": [\"40149658\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NK receptor that reads I-antigen not identified\", \"No in vivo immune validation\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Implicated GCNT2 in osteoblast differentiation upstream of PI3K/AKT/mTOR signaling.\",\n      \"evidence\": \"Knockdown in MC3T3-E1 osteoblasts with differentiation markers and LY294002 inhibitor rescue\",\n      \"pmids\": [\"41298859\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Pharmacological inhibitor only, no direct pathway confirmation\", \"Single cell-line model, no in vivo data\", \"Glycan substrate linking GCNT2 to PI3K signaling not identified\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Reinforced that the exon-1B GCNT2B transcript is clinically required for lens function via an isoform-restricted truncating variant.\",\n      \"evidence\": \"Next-generation sequencing and copy-number mapping with genotype-phenotype correlation in a cataract case\",\n      \"pmids\": [\"41813616\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single case report, no biochemical validation\", \"Variant effect on enzyme activity not measured\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GCNT2's I-branching produces opposite tumor outcomes across tissues, and which receptors and glycan sites mediate immune and signaling effects, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of isoform-specific substrate selection\", \"Direct glycan acceptor sites on IGF receptors/integrins unmapped\", \"NK receptor recognizing I-antigen unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"B3GNT2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":5,"faith_pct":80.0}}